Suven Life Sciences to Present Three Posters on Samelisant at SLEEP-2026 Annual Meeting
Hyderabad, India (June 12, 2026) - Suven Life Sciences Limited, a clinical-stage biopharmaceutical company specializing in CNS disorder treatments, announced that it will present three posters detailing the clinical advancement of Samelisant (SUVN-G3031) at the SLEEP-2026 Annual Meeting. The event is hosted by the Associated Professional Sleep Societies (APSS), LLC and will take place in Baltimore, USA, from June 14-17, 2026.The APSS meeting, which is a joint venture of the American Academy of Sleep Medicine and the Sleep Research Society, serves as a premier scientific forum focusing on sleep medicine, circadian research, and sleep health. SLEEP 2026 is expected to host over 5,000 attendees, speakers, and exhibitors, alongside more than 140 exhibits and 1,500 research abstract presentations.
The three presentations will provide insight into Samelisant’s progress. These include positive Phase-2 efficacy data in excessive daytime sleepiness (EDS), the design and rationale for a Phase-2 study concerning cataplexy in Type 1 narcolepsy patients, and the Phase-3 development strategy for Samelisant during the AWAKE study targeting narcolepsy.
The poster presentations are scheduled as follows:
| Presentation Focus | Date | Poster Number |
|---|---|---|
| Samelisant (SUVN-G3031) reduces Excessive Daytime Sleepiness in Narcolepsy Patients: Phase-2 Results | June 15, 2026 | # 374 |
| Study Design and Rationale for a Phase-2 Study of Samelisant (SUVN-G3031) for Cataplexy in Type 1 Narcolepsy | June 15, 2026 | # 368 |
| Phase-3 Clinical Development of Samelisant: Rationale and Study Design for Treating EDS in Narcolepsy | June 16, 2026 | # 332 |
Members of Suven’s scientific team will also be stationed at Exhibit booth # 1034 to conduct meetings with potential partnering companies, Key Opinion Leaders (KOLs), and Principal Investigators involved in the Phase-3 study.
Suven Life Sciences Limited is dedicated to discovering and clinically developing innovative medicines for CNS disorders. The company maintains a portfolio of advanced clinical candidates across several focus areas, including Alzheimer's disease (AD), Major Depressive Disorder (MDD), Parkinson's Disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders.
Key pipeline assets include:
- Masupirdine (SUVN-502): A Global Phase-3 study targeting agitation in dementia of the Alzheimer's type.
- Samelisant (SUVN-G3031): Focused on excessive daytime sleepiness (EDS) in narcolepsy. The company has completed a Phase-2 study for EDS and is planning both a Phase-2 study for Cataplexy and a pivotal Phase-3 study for EDS.
- Ropanicant (SUVN-911): An open-label Phase 2a study focusing on MDD, with the recruitment for a double blind randomized Placebo controlled Phase-2b study completed.
- Usmarapride (SUVN-D4010): A Phase-2 study is currently in planning for cognitive disorders.
- SUVN-I6107: A Phase-1 study targeting cognitive disorders that is currently in progress.
In addition to these clinical assets, Suven has seven research projects within its pipeline across various indications and retains all intellectual property rights for its assets globally.
SUVEN Stock Price Movement
Edging higher in live trading, shares of Suven Life Sciences Limited rally to reach ₹271.90 as of 11:37 AM today, surging 3.33%. The stock trades within its current session range, having moved between a low of ₹265.20 and a high of ₹273.70 so far.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.